BeyondSpring (BYSI) puts more active than calls
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- BuzzFeed cuts 35% of workforce in restructuring move
BeyondSpring (BYSI) Appoints Mark Santos to its Board
November 10, 2021 7:05 AM ESTBeyondSpring Pharmaceuticals (NASDAQ: BYSI), a clinical stage biopharmaceutical company focused on the development of innovative cancer therapeutics, today announced the appointment of Mark Santos, RPh, to its Board of Directors, effective immediately. Mr. Santos has over 30 years of executive experience across the healthcare and pharmaceutical industries, currently serving as the Senior Vice President of Pharma Strategy & Contracting at OneOncology. He was President of ION Solutions, the leading GPO in the U.S., from 2011 to 2018.
Were honored to have industry veteran... More
